Author details

Full Name

Ruiying Zhao

Affiliation

ORCID

Career Start Year

2005

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37067901	Li-Fraumeni Syndrome-Associated Dimer-Forming Mutant p53 Promotes Transactivation-Independent Mitochondrial Cell Death.		2023
36973285	Rewired m<sup>6</sup>A epitranscriptomic networks link mutant p53 to neoplastic transformation.	Nat Commun	2023
37197432	Molecular mechanisms of osteosarcoma metastasis and possible treatment opportunities.		2023
35412907	Hereditary retinoblastoma iPSC model reveals aberrant spliceosome function driving bone malignancies.	Proc Natl Acad Sci U S A	2022
35894945	CBX8 Together with SET Facilitates Ovarian Carcinoma Growth and Metastasis by Suppressing the Transcription of SUSD2.	Mol Cancer Res	2022
34831045	Cardiotoxicity of Antineoplastic Therapies and Applications of Induced Pluripotent Stem Cell-Derived Cardiomyocytes.	Cells	2021
34127794	Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML.	Leukemia	2021
33609419	Impact of diabetes on promoting the growth of breast cancer.	Cancer Communications	2021
34965247	Patient-derived iPSCs link elevated mitochondrial respiratory complex I function to osteosarcoma in Rothmund-Thomson syndrome.	PLoS Genet	2021
33022533	Modeling of osteosarcoma with induced pluripotent stem cells.	Stem Cell Research	2020
31939194	Engineering Mutation Clones in Mammalian Cells with CRISPR/Cas9.	Methods in Molecular Biology	2020
32492708	Circulating Myeloid-derived Suppressor Cells Facilitate Invasion of Thyroid Cancer Cells by Repressing miR-486-3p.	Journal of Clinical Endocrinology and Metabolism	2020
33519915	LncRNA H19 Suppresses Osteosarcomagenesis by Regulating snoRNAs and DNA Repair Protein Complexes.	Frontiers in Genetics	2020
30949405	Irradiation-induced dynamic changes of gene signatures reveal gain of metastatic ability in nasopharyngeal carcinoma.	American Journal of Cancer Research (discontinued)	2019
30640060	Generation of a heterozygous p53 R249S mutant human embryonic stem cell line by TALEN-mediated genome editing.	Stem Cell Research	2019
31127149	Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia.	Leukemia	2019
31390555	Genomic Integrity Safeguards Self-Renewal in Embryonic Stem Cells.	Cell Rep	2019
29730572	Establishment of a human embryonic stem cell line with homozygous TP53 R248W mutant by TALEN mediated gene editing.	Stem Cell Research	2018
30312871	Generation of an induced pluripotent stem cell line from an individual with a heterozygous RECQL4 mutation.	Stem Cell Research	2018
30069853	Induced Pluripotent Stem Cells and Induced Pluripotent Cancer Cells in Cancer Disease Modeling.	Advances in Experimental Medicine and Biology	2018
29985349	Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells.	Journal of Visualized Experiments	2018
29490944	Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition.	Cancer Res	2018
29414603	A homozygous p53 R282W mutant human embryonic stem cell line generated using TALEN-mediated precise gene editing.	Stem Cell Research	2018
29414415	Generation of human embryonic stem cell line with heterozygous RB1 deletion by CRIPSR/Cas9 nickase.	Stem Cell Research	2018
28143883	FZR1 loss increases sensitivity to DNA damage and consequently promotes murine and human B-cell acute leukemia.	Blood	2017
28735817	Osteosarcoma: Molecular Pathogenesis and iPSC Modeling.	Trends in Molecular Medicine	2017
28818333	Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53.	Trends Pharmacol Sci	2017
28626837	The Histogenesis of Ewing Sarcoma.		2017
25860607	Modeling familial cancer with induced pluripotent stem cells.	Cell	2015
24957076	Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer.	J Natl Cancer Inst	2014
25395170	CSN6 drives carcinogenesis by positively regulating Myc stability.	Nature Communications	2014
23421998	CDK inhibitor p57 (Kip2) is downregulated by Akt during HER2-mediated tumorigenicity.	Cell Cycle	2013
22264792	KrasG12D-induced IKK2/Î²/NF-ÎºB activation by IL-1Î± and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.	Cancer Cell	2012
22374676	MiR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN.	Cell Cycle	2012
22862944	Regulation of embryonic and induced pluripotency by aurora kinase-p53 signaling.	Cell Stem Cell	2012
23102701	Nuclear pore component Nup98 is a potential tumor suppressor and regulates posttranscriptional expression of select p53 target genes.	Mol Cell	2012
23187808	CDK inhibitor p57 (Kip2) is negatively regulated by COP9 signalosome subunit 6.	Cell Cycle	2012
23095642	HER2-Akt signaling in regulating COP9 signalsome subunit 6 and p53.	Cell Cycle	2012
21876386	Roles of COP9 signalosome in cancer.	Cell Cycle	2011
21317535	Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers.	Journal of Clinical Investigation	2011
21135113	14-3-3sigma exerts tumor-suppressor activity mediated by regulation of COP1 stability.	Cancer Research	2011
21448323	Exenatide improves glucocorticoid-induced glucose intolerance in mice.	Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy	2011
21625211	COP9 signalosome subunit 6 stabilizes COP1, which functions as an E3 ubiquitin ligase for 14-3-3Ï¿.	Oncogene	2011
20843328	Nuclear export regulation of COP1 by 14-3-3Ï¿ in response to DNA damage.	Molecular Cancer	2010
19528349	Hypoxia-mediated up-regulation of Pim-1 contributes to solid tumor formation.	American Journal of Pathology	2009
19483729	Pim-1 plays a pivotal role in hypoxia-induced chemoresistance.	Oncogene	2009
18769123	Autophagy induced by farnesyltransferase inhibitors in cancer cells.	Cancer Biology and Therapy	2008
16532026	Negative cell cycle regulator 14-3-3sigma stabilizes p27 Kip1 by inhibiting the activity of PKB/Akt.	Oncogene	2006
16540659	DNA damage-induced protein 14-3-3 sigma inhibits protein kinase B/Akt activation and suppresses Akt-activated cancer.	Cancer Research	2006
16505098	14-3-3sigma, a p53 regulator, suppresses tumor growth of nasopharyngeal carcinoma.	Molecular Cancer Therapeutics	2006